Bulletin
Investor Alert

Market Pulse Archives

Oct. 14, 2021, 6:17 a.m. EDT

Coronavirus tally: Global cases of COVID-19 top 239 million as FDA panel meets on Moderna booster

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    Johnson & Johnson (JNJ)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

The global tally for the coronavirus-borne illness climbed above 239 million on Thursday, while the death toll edged above 4.87 million, according to data aggregated by Johns Hopkins University . The U.S. continues to lead the world with a total of 44.7 million cases and 719,530 deaths. The U.S. is averaging close to 1,900 deaths a day, according to a New York Times tracker, , although new cases and hospitalizations are declining. a Food and Drug Administration advisory committee will meet later Thursday to discuss and take a vote on whether to authorize a booster dose for people vaccinated with the Moderna /zigman2/quotes/205619834/composite MRNA -4.45% vaccine. The committee will reconvene on Friday to discuss boosters for the Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -0.23% shot. India is second by cases after the U.S. at 34 million and has suffered 451,435 deaths. Brazil has second highest death toll at 601,574 and 21.6 million cases. In Europe, Russia has most fatalities at 215,438, followed by the U.K. at 138,487.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 160.07
-7.45 -4.45%
Volume: 11.80M
Jan. 21, 2022 4:00p
P/E Ratio
9.83
Dividend Yield
N/A
Market Cap
$64.90 billion
Rev. per Employee
$9.10M
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 164.87
-0.38 -0.23%
Volume: 10.55M
Jan. 21, 2022 4:00p
P/E Ratio
24.64
Dividend Yield
2.57%
Market Cap
$434.04 billion
Rev. per Employee
$679,695
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.